15692469

Source:http://linkedlifedata.com/resource/pubmed/id/15692469

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0003241, umls-concept:C0011615, umls-concept:C0021270, umls-concept:C0023977, umls-concept:C0042196, umls-concept:C1099414, umls-concept:C1378128, umls-concept:C1527148
pubmed:issue	2
pubmed:dateCreated	2005-2-4
pubmed:abstractText	We investigated whether treatment of atopic dermatitis with pimecrolimus cream 1% in infants affects the development of a normal antibody response to vaccinations.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/7907132
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Bacterial, http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Viral, http://linkedlifedata.com/resource/pubmed/chemical/Diphtheria Toxoid, http://linkedlifedata.com/resource/pubmed/chemical/Immunosuppressive Agents, http://linkedlifedata.com/resource/pubmed/chemical/Measles Vaccine, http://linkedlifedata.com/resource/pubmed/chemical/Ointments, http://linkedlifedata.com/resource/pubmed/chemical/Rubella Vaccine, http://linkedlifedata.com/resource/pubmed/chemical/Tacrolimus, http://linkedlifedata.com/resource/pubmed/chemical/Tetanus Toxoid, http://linkedlifedata.com/resource/pubmed/chemical/pimecrolimus
pubmed:status	MEDLINE
pubmed:month	Feb
pubmed:issn	1097-6787
pubmed:author	pubmed-author:BarbierNathalieN, pubmed-author:BreuerKristineK, pubmed-author:DavidsonMiles JMJ, pubmed-author:GoertzHans-PeterHP, pubmed-author:MeurerMichaelM, pubmed-author:OrtonneJean-PaulJP, pubmed-author:PappKim AKA, pubmed-author:PaulCarleC, pubmed-author:PotterPaul CPC, pubmed-author:de ProstYvesY
pubmed:issnType	Electronic
pubmed:volume	52
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	247-53
pubmed:dateRevised	2006-11-15
pubmed:meshHeading	pubmed-meshheading:15692469-Administration, Cutaneous, pubmed-meshheading:15692469-Antibodies, Bacterial, pubmed-meshheading:15692469-Antibodies, Viral, pubmed-meshheading:15692469-Antibody Formation, pubmed-meshheading:15692469-Clostridium tetani, pubmed-meshheading:15692469-Corynebacterium diphtheriae, pubmed-meshheading:15692469-Dermatitis, Atopic, pubmed-meshheading:15692469-Diphtheria Toxoid, pubmed-meshheading:15692469-Double-Blind Method, pubmed-meshheading:15692469-Female, pubmed-meshheading:15692469-Follow-Up Studies, pubmed-meshheading:15692469-Humans, pubmed-meshheading:15692469-Immunosuppressive Agents, pubmed-meshheading:15692469-Infant, pubmed-meshheading:15692469-Male, pubmed-meshheading:15692469-Measles Vaccine, pubmed-meshheading:15692469-Measles virus, pubmed-meshheading:15692469-Ointments, pubmed-meshheading:15692469-Prospective Studies, pubmed-meshheading:15692469-Rubella Vaccine, pubmed-meshheading:15692469-Rubella virus, pubmed-meshheading:15692469-Tacrolimus, pubmed-meshheading:15692469-Tetanus Toxoid, pubmed-meshheading:15692469-Vaccination
pubmed:year	2005
pubmed:articleTitle	Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination.
pubmed:affiliation	Probity Medical Research, Waterloo, Ontario, Canada. kapapp@probitymedical.com
pubmed:publicationType	Journal Article, Clinical Trial, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study